Oncolytic viruses as platform for multimodal cancer therapeutics: A promising land

Cancer Gene Therapy

Volumn 21, Issue 7, 2014, Pages 261-263

  Guo, Z S ^a   Bartlett, D L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; ONCOLYTIC VIRUS;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; VASCULARIZATION; ANIMAL; NEOPLASMS; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84904689153     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.31     Document Type: Review

References (20)

1. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 2013; 12: 103
2. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014; 4: 74
3. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2014; 2: 295-300
4. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: Combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-263
5. Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998; 16: 444-448
6. Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y et al. Oncolytic virusmediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012; 104: 42-55
7. Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T et al. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol 2014; 88: 5263-5276
8. Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V et al. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-Alpha signaling. Oncogene 2014; 33: 1700-1712
9. Angarita FA, Acuna SA, Ottolino-Perry K, Zerhouni S, McCart JA. Mounting a strategic offense: Fighting tumor vasculature with oncolytic viruses. Trends Mol Med 2013; 19: 378-392
10. Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting CXCL12/ CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci USA 2013; 110: E1291-E1300
11. Gil M, Bieniasz M, Seshadri M, Fisher D, Ciesielski MJ, Chen Y et al. Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br J Cancer 2011; 105: 1512-1521
12. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079
13. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: Molecular targets in tumorselective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231
14. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011; 17: 3686-3696
15. Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M et al. Targeting gallbladder cancer: Oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer 2014; 13: 82
16. Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014; 32: 182-190
17. Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.Mol Ther 2011; 19: 650-657
18. Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res 2013; 1: 309-319
19. Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-Armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol Ther 2014; 22: 102-111
20. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014; 6: 226ra32.